Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

Key Points

• This research aims to explore the occurrence of interstitial lung disease in multiple sclerosis patients treated with ocrelizumab.
• Case series involving 6 patients with multiple sclerosis
• Long-term treatment with ocrelizumab
• Observation of respiratory symptoms
• Interstitial lung disease was identified in 6 patients
• All patients were on long-term ocrelizumab therapy
• Symptoms involved respiratory distress and imaging findings